lupus.bmj9h
Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
Objective Long-term glucocorticoid use in SLE may have significant side effects; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups. Therefore, we evaluated the ...
lupus.bmj5d
LP-078 Characterization of a cohort of patients with a diagnosis of systemic lupus erythematosus followed-up in the city of Cali, Colombia
Background The course and evolution of the SLE depends on the affected organ, adherence to treatment and accumulated organ damage, but ethnicity plays a fundamental role, leading to worse results in ...
lupus.bmj5d
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
Objectives To evaluate the time course of clinical response following anifrolumab treatment in patients with SLE. Methods A post hoc analysis was conducted using pooled data from phase III, randomised ...
lupus.bmj4d
Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus
Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This ...
lupus.bmj6d
Prevalence of coronary artery calcification in young patients with SLE of predominantly Hispanic and African–American descent
Objectives Cardiovascular disease (CVD) is a leading cause of death in SLE. Coronary artery calcium (CAC) scores predict CVD events, independent of traditional risk factors. Patients with SLE aged >45 ...
lupus.bmj4d
LP-091 Neutrophil extracellular traps in APS and SLE
1 Laboratory of Thromboinflammation, Nasonova Research Institute of Rheumatology, Russian Federation 2 Laboratories of biomedical research methods, Moscow Regional Clinical Research Institute named ...